Bright Minds Biosciences Inc. today announced the launch of a public offering to raise aggregate gross proceeds of US$100 million through the issuance of common shares and, at investors’ election, pre-funded warrants. The offering includes up to 15% additional shares under a 30-day over-allotment option granted to the joint book-running managers. Proceeds will be raised in the United States under a shelf registration statement declared effective by the SEC on September 2, 2025.

Net proceeds from the offering will support the advancement of the Company’s pipeline, including late-stage clinical trials for absence seizures, developmental and encephalopathic epilepsies (DEE), and Prader-Willi Syndrome. Funds will also initiate the phase 1 trial of BMB-105 and bolster earlier-stage research programs. Remaining capital will be used for general corporate purposes and working capital, ensuring continuity of operations through key data readouts and regulatory milestones.

Jefferies, TD Cowen, Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers. Each firm will coordinate book-building and distribution efforts across institutional and high-net-worth channels. The underwriter group will receive customary commissions and expense reimbursements, while the over-allotment option adds flexibility to increase issuance by up to 15% in the event of strong investor demand.

The offering is made solely by means of a prospectus supplement and the base prospectus included in the Form F-3 registration statement filed with the SEC. Copies of both documents will be available on the SEC’s EDGAR system and from each book-running manager upon request. Investors are urged to review these materials, including the sections on risk factors and forward-looking statements, before making an investment decision.